Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing

Hepatitis C virus (HCV) is a leading cause of morbidity and mortality worldwide. Despite the considerable reduction in the number of HCV infections in recent years, there are still ca. 399 000 deaths each year largely due to hepatitis C-related liver disease [1]. Remarkable advances have been made in the treatment of HCV infection, notably with the introduction of direct-acting antivirals (DAAs). However, as a highly variable virus with many quasispecies, HCV can select in vitro and in vivo resistance-associated substitutions (RASs) to antivirals, in particular to anti-NS5A owing to their low genetic barrier [2].

Source: International Journal of Antimicrobial Agents - September 17, 2018 Category: Drugs & Pharmacology Authors: Thuy Nguyen, Sepideh Akhavan, Fabienne Caby, Luminita Bonyhay, Lucile Larrouy, Anne Gervais, Pascal Lebray, Thierry Poynard, Yvon Calmus, Anne Simon, Marc-Antoine Valantin, Vincent Calvez, Anne-Genevi ève Marcelin, Eve Todesco Tags: Short Communication Source Type: research